Characteristic | Normal Weight n = 153 (%) | Excessive weight gain n = 12 (%) | Crude OR (95%CI) | P-value | Adjusted OR (95%CI) | P-value |
---|---|---|---|---|---|---|
Sex | Â | Â | Â | Â | Â | Â |
Male | 85 (55.6) | 0 | 1.00 | Â | Â | Â |
Female | 68 (44.4) | 12 (100) | ∞ |  |  |  |
ART experience | Â | Â | Â | Â | Â | Â |
Treatment-naïve prior DTG start | 13 (8.5) | 0 | 1.00 (ref) |  |  |  |
Treatment-experienced prior DTG start | 140 (91.5) | 12 (100) | ∞ |  |  |  |
NRTI backbone prior DTG start | Â | Â | Â | Â | Â | Â |
Abacavir-based | 57 (40.7) | 4 (33.3) | 1.00 | Â | Â | Â |
Zidovudine-based | 63 (45.0) | 7 (58.3 | 1.58 (0.44–5.69) | 0.482 |  |  |
TDF-based | 20 (14.3) | 1 (8.3) | 0.71 (0.08–6.76) | 0.768 |  |  |
NNRTI backbone* prior DTG start | Â | Â | Â | Â | Â | Â |
EFV/NVP-based | 101(72.1) | 8 (66.7) | 1.00 (ref) | Â | Â | Â |
PI-based | 39 (27.9) | 4 (33.7) | 1.29 (0.37–4.55) | 0.687 |  |  |
Duration on DTG | Â | Â | Â | Â | Â | Â |
1-<2yr | 39 (25.5) | 4 (33.3) | 1.00 (ref) | Â | 1.00 (ref) | Â |
2-<3yr | 46 (30.1) | 3 (25.0) | 0.64 (0.13–3.02) | 0.569 | 0.60 (0.12–2.96) | 0.380 |
3- <5yr | 68 (44.4) | 5 (41.7) | 0.73 (0.18–2.83) | 0.635 | 0.88 (0.21–3.69) | 0.939 |
Viral load at DTG start | Â | Â | Â | Â | Â | Â |
Unsuppressed (≥ 1,000 copies/ml) | 5 (3.3) | 0 | 1.00 (ref) |  |  |  |
Suppressed (< 1,000 copies/ml) | 133 (86.9) | 12 (100) | ∞ |  |  |  |
Unknown/Not applicable | 15 (9.8) | 0 | ∞ |  |  |  |
Current viral load | Â | Â | Â | Â | Â | Â |
Unsuppressed (≥ 1,000 copies/ml) | 5 (3.3) | 0 | ∞ |  |  |  |
Suppressed (< 1,000copies/ml) | 142 (92.8) | 11 (91.7) | 0.46(0.05–4.21) | 0.496 | 041(0.04–4.24) | 0.453 |
Unknown/Not applicable | 6 (3.9) | 1 (8.3) | ∞ |  | ∞ |  |
Experienced drug side effects after DTG start | Â | Â | Â | Â | Â | Â |
No | 130 (85.0) | 7 (58.3) | 1.00 (ref) | Â | 1.00 (ref) | Â |
Yes | 23 (15.0) | 5 (41.7) | 4.04 (1.18–13.8) | 0.026 | 4.20 (1.20-14.71) | 0.025 |
Physical activity | Â | Â | Â | Â | Â | Â |
No | 26 (17.0) | 4 (33.3) | 1.00 (ref) | Â | Â | Â |
Yes | 127 (83.0) | 8 (66.7) | 0.41 (0.11–1.46) | 0.169 |  |  |
Previous opportunistic infections | Â | Â | Â | Â | Â | Â |
No | 147 (96.1) | 11 (91.7) | 1.00 (ref) | Â | Â | Â |
Yes | 6 (3.9) | 1 (8.3) | 2.23 (0.25–20.2) | 0.476 |  |  |
Blood pressure | Â | Â | Â | Â | Â | Â |
Normal (< 90th percentile /<120/80 mmHg) | 90 (58.8) | 8 (66.7) | 1.00 (ref |  |  |  |
Elevated (≥ 90th percentile /≥120/80mmHg) | 63 (41.2) | 4 (33.3) | 0.714 (0.21–2.46) | 0.596 |  |  |
Blood glucose | Â | Â | Â | Â | Â | Â |
Normal | 141 (92.2) | 12 (100) | 1.00 (ref) | Â | Â | Â |
Pre-diabetic | 12 (7.8) | 0 | ∞ |  |  |  |
High | 0 | 0 | ∞ |  |  |  |
Triglycerides | Â | Â | Â | Â | Â | Â |
Acceptable (< 90 mg/dl) | 90 (58.8) | 9 (75.0) | 1.00 (ref) |  |  |  |
Borderline High (90-129 mg/dl) | 47 (30.5) | 3 (25.0) | 0.64 (0.16–2.87) | 0.516 |  |  |
High (≥ 130 mg/dl) | 16 (10.5) | 0 | ∞ |  |  |  |
Total cholesterol | Â | Â | Â | Â | Â | Â |
Acceptable (< 170 mg/dl) | 141 (92.2) | 10 (83.3) | 1.00 (ref) |  |  |  |
Borderline High (170-199 mg/dl) | 12 (7.8) | 1 (8.3) | 1.18 (0.14–9.94) | 0.882 |  |  |
High (≥ 200 mg/dl) | 0 | 1 (8.3) | ∞ |  |  |  |
Low density lipoprotein cholesterol | Â | Â | Â | Â | Â | Â |
Acceptable (< 110 mg/dl) | 142 (92.8) | 10 (83.3) | 1.00 (ref) |  |  |  |
Borderline High (110-129 mg/dl) | 11 (7.2) | 2 (16.7) | 2.58 (0.50–13.2) | 0.256 |  |  |
High (≥ 130 mg/dl) | 0 | 0 | ∞ |  |  |  |
High density lipoprotein cholesterol | Â | Â | Â | Â | Â | Â |
Acceptable (> 45 mg/dl) | 30 (19.6) | 4 (33.3) | 1.00 (ref) |  |  |  |
Borderline Low (40-45 mg/dl) | 33 (21.6) | 3 (25.0) | 0.68 (0.14–3.29) | 0.634 |  |  |
Low (< 40 mg/dl) | 90(58.8) | 5 (41.7) | 0.42 (0.11–1.65) | 0.213 |  |  |